These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 33448580)

  • 1. Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: a SPRINT substudy.
    Vaduganathan M; Pareek M; Kristensen AMD; Biering-Sørensen T; Byrne C; Almarzooq Z; Olesen TB; Olsen MH; Bhatt DL
    Eur J Heart Fail; 2021 Mar; 23(3):384-392. PubMed ID: 33448580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic Kidney Disease Stage and Cardiovascular and Mortality Events Among Older Adults: The SPRINT Trial.
    Turbay-Caballero V; Ricardo AC; Chen J; Missikpode C; Lash JP; Aroca-Martinez G; Musso CG
    Kidney Med; 2024 Jul; 6(7):100845. PubMed ID: 38966681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes.
    Filippatos G; Anker SD; Pitt B; Rossing P; Joseph A; Kolkhof P; Lambelet M; Lawatscheck R; Bakris GL; Ruilope LM; Agarwal R
    JACC Heart Fail; 2022 Nov; 10(11):860-870. PubMed ID: 36328655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A
    Waijer SW; Gansevoort RT; Bakris GL; Correa-Rotter R; Hou FF; Kohan DE; Kitzman DW; Makino H; McMurray JJV; Perkovic V; Tobe S; Parving HH; de Zeeuw D; Heerspink HJL
    Clin J Am Soc Nephrol; 2021 Dec; 16(12):1824-1832. PubMed ID: 34853062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure: A Secondary Analysis of EMPEROR-Pooled.
    Ferreira JP; Zannad F; Butler J; Filippatos G; Pocock SJ; Brueckmann M; Steubl D; Schueler E; Anker SD; Packer M
    JAMA Cardiol; 2022 Nov; 7(11):1148-1159. PubMed ID: 36129693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Intensive Blood Pressure Control in Patients with and without Albuminuria:
    Chang AR; Kramer H; Wei G; Boucher R; Grams ME; Berlowitz D; Bhatt U; Cohen DL; Drawz P; Punzi H; Freedman BI; Haley W; Hawfield A; Horwitz E; McLouth C; Morisky D; Papademetriou V; Rocco MV; Wall B; Weiner DE; Zias A; Beddhu S;
    Clin J Am Soc Nephrol; 2020 Aug; 15(8):1121-1128. PubMed ID: 32669306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kidney Disease, Hypertension Treatment, and Cerebral Perfusion and Structure.
    Kurella Tamura M; Gaussoin S; Pajewski NM; Zaharchuk G; Freedman BI; Rapp SR; Auchus AP; Haley WE; Oparil S; Kendrick J; Roumie CL; Beddhu S; Cheung AK; Williamson JD; Detre JA; Dolui S; Bryan RN; Nasrallah IM;
    Am J Kidney Dis; 2022 May; 79(5):677-687.e1. PubMed ID: 34543687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kidney function measures and cardiovascular outcomes in people with diabetes: the Hoorn Diabetes Care System cohort.
    Dal Canto E; Elders PJM; van der Heijden AA; van Ballegooijen AJ; Lissenberg-Witte BI; Rutters F; Beulens JWJ
    Diabetologia; 2023 Mar; 66(3):482-494. PubMed ID: 36347992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone.
    Agarwal R; Pitt B; Rossing P; Anker SD; Filippatos G; Ruilope LM; Kovesdy CP; Tuttle K; Vaduganathan M; Wanner C; Bansilal S; Gebel M; Joseph A; Lawatscheck R; Bakris GL
    JAMA Cardiol; 2023 Aug; 8(8):732-741. PubMed ID: 37314801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis.
    ; Grams ME; Coresh J; Matsushita K; Ballew SH; Sang Y; Surapaneni A; Alencar de Pinho N; Anderson A; Appel LJ; Ärnlöv J; Azizi F; Bansal N; Bell S; Bilo HJG; Brunskill NJ; Carrero JJ; Chadban S; Chalmers J; Chen J; Ciemins E; Cirillo M; Ebert N; Evans M; Ferreiro A; Fu EL; Fukagawa M; Green JA; Gutierrez OM; Herrington WG; Hwang SJ; Inker LA; Iseki K; Jafar T; Jassal SK; Jha V; Kadota A; Katz R; Köttgen A; Konta T; Kronenberg F; Lee BJ; Lees J; Levin A; Looker HC; Major R; Melzer Cohen C; Mieno M; Miyazaki M; Moranne O; Muraki I; Naimark D; Nitsch D; Oh W; Pena M; Purnell TS; Sabanayagam C; Satoh M; Sawhney S; Schaeffner E; Schöttker B; Shen JI; Shlipak MG; Sinha S; Stengel B; Sumida K; Tonelli M; Valdivielso JM; van Zuilen AD; Visseren FLJ; Wang AY; Wen CP; Wheeler DC; Yatsuya H; Yamagata K; Yang JW; Young A; Zhang H; Zhang L; Levey AS; Gansevoort RT
    JAMA; 2023 Oct; 330(13):1266-1277. PubMed ID: 37787795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalbuminuric Diabetic Kidney Disease and Risk of All-Cause Mortality and Cardiovascular and Kidney Outcomes in Type 2 Diabetes: Findings From the Hong Kong Diabetes Biobank.
    Jin Q; Luk AO; Lau ESH; Tam CHT; Ozaki R; Lim CKP; Wu H; Jiang G; Chow EYK; Ng JK; Kong APS; Fan B; Lee KF; Siu SC; Hui G; Tsang CC; Lau KP; Leung JY; Tsang MW; Kam G; Lau IT; Li JK; Yeung VT; Lau E; Lo S; Fung S; Cheng YL; Chow CC; Huang Y; Lan HY; Szeto CC; So WY; Chan JCN; Ma RCW;
    Am J Kidney Dis; 2022 Aug; 80(2):196-206.e1. PubMed ID: 34999159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.
    Damman K; Gori M; Claggett B; Jhund PS; Senni M; Lefkowitz MP; Prescott MF; Shi VC; Rouleau JL; Swedberg K; Zile MR; Packer M; Desai AS; Solomon SD; McMurray JJV
    JACC Heart Fail; 2018 Jun; 6(6):489-498. PubMed ID: 29655829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid kidney function decline and increased risk of heart failure in patients with type 2 diabetes: findings from the ACCORD cohort : Rapid kidney function decline and heart failure in T2D.
    Bueno Junior CR; Bano A; Tang Y; Sun X; Abate A; Hall E; Mitri J; Morieri ML; Shah H; Doria A
    Cardiovasc Diabetol; 2023 Jun; 22(1):131. PubMed ID: 37365586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria.
    Sarraju A; Bakris G; Cannon CP; Cherney D; Damaraju CV; Figtree GA; Gogate J; Greene T; Heerspink HJL; Januzzi JL; Neal B; Jardine MJ; Blais J; Kosiborod M; Levin A; Lingvay I; Weir MR; Perkovic V; Mahaffey KW
    J Am Coll Cardiol; 2022 Nov; 80(18):1721-1731. PubMed ID: 36302584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kidney Function as Risk Factor and Predictor of Cardiovascular Outcomes and Mortality Among Older Adults.
    Kühn A; van der Giet M; Kuhlmann MK; Martus P; Mielke N; Ebert N; Schaeffner ES
    Am J Kidney Dis; 2021 Mar; 77(3):386-396.e1. PubMed ID: 33197533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis.
    Rossing P; Bain SC; Bosch-Traberg H; Sokareva E; Heerspink HJL; Rasmussen S; Mellbin LG
    Cardiovasc Diabetol; 2023 Aug; 22(1):220. PubMed ID: 37620807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure.
    Tye SC; Jongs N; Coca SG; Sundström J; Arnott C; Neal B; Perkovic V; Mahaffey KW; Vart P; Heerspink HJL
    Cardiovasc Diabetol; 2022 Sep; 21(1):194. PubMed ID: 36151557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated urine albumin-to-creatinine ratio increases the risk of new-onset heart failure in patients with type 2 diabetes.
    Tao J; Sang D; Zhen L; Zhang X; Li Y; Wang G; Chen S; Wu S; Zhang W
    Cardiovasc Diabetol; 2023 Mar; 22(1):70. PubMed ID: 36966320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CVD risk in non-albuminuric chronic kidney disease in hypertensive, non-diabetic subjects: A
    Sheng CS; Wang D; Yuan J; Cheng Y; Sun S; Yang Y; Miao Y; Wang W; Tian J; Bloomgarden ZT
    Front Cardiovasc Med; 2022; 9():977938. PubMed ID: 36568559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive Function and Kidney Disease: Baseline Data From the Systolic Blood Pressure Intervention Trial (SPRINT).
    Weiner DE; Gaussoin SA; Nord J; Auchus AP; Chelune GJ; Chonchol M; Coker L; Haley WE; Killeen AA; Kimmel PL; Lerner AJ; Oparil S; Saklayen MG; Slinin YM; Wright CB; Williamson JD; Kurella Tamura M;
    Am J Kidney Dis; 2017 Sep; 70(3):357-367. PubMed ID: 28606731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.